About: Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies
Creator	Lynfield, Ruth Uyeki, Timothy Cholewinska, Grazyna Cozzi-Lepri, Alessandro Davey, Richard David, Daniel Herman-Lamin, Kathy Kuetter, Stefan Lundgren, Jens Ternesgen, Zelalem Wentworth, Deborah Losso, Marcelo Clifford Lane, H Dwyer, Dominic Neaton, James
topic	covid:0542a6ae26f57a5ffa35dcfebdec5004ff45688c#this
Source	PMC
abstract	BACKGROUND: Data from prospectively planned cohort studies on risk of major clinical outcomes and prognostic factors for patients with influenza A(H1N1)pdm09 virus are limited. In 2009, in order to assess outcomes and evaluate risk factors for progression of illness, two cohort studies were initiated: FLU 002 in outpatients and FLU 003 in hospitalized patients. METHODS AND FINDINGS: Between October 2009 and December 2012, adults with influenza-like illness (ILI) were enrolled; outpatients were followed for 14 days and inpatients for 60 days. Disease progression was defined as hospitalization and/or death for outpatients, and hospitalization for >28 days, transfer to intensive care unit (ICU) if enrolled from general ward, and/or death for inpatients. Infection was confirmed by RT-PCR. 590 FLU 002 and 392 FLU 003 patients with influenza A (H1N1)pdm09 were enrolled from 81 sites in 17 countries at 2 days (IQR 1–3) and 6 days (IQR 4–10) following ILI onset, respectively. Disease progression was experienced by 29 (1 death) outpatients (5.1%; 95% CI: 3.4–7.2%) and 80 inpatients [death (32), hospitalization >28 days (43) or ICU transfer (20)] (21.6%; 95% CI: 17.5–26.2%). Disease progression (death) for hospitalized patients was 53.1% (26.6%) and 12.8% (3.8%), respectively, for those enrolled in the ICU and general ward. In pooled analyses for both studies, predictors of disease progression were age, longer duration of symptoms at enrollment and immunosuppression. Patients hospitalized during the pandemic period had a poorer prognosis than in subsequent seasons. CONCLUSIONS: Patients with influenza A(H1N1)pdm09, particularly when requiring hospital admission, are at high risk for disease progression, especially if they are older, immunodeficient, or admitted late in infection. These data reinforce the need for international trials of novel treatment strategies for influenza infection and serve as a reminder of the need to monitor the severity of seasonal and pandemic influenza epidemics globally. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: FLU 002- NCT01056354, FLU 003- NCT01056185.
has issue date	2014-07-08(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0101785
bibo:pmid	25004134
has license	cc0
sha1sum (hex)	0542a6ae26f57a5ffa35dcfebdec5004ff45688c
schema:url	https://doi.org/10.1371/journal.pone.0101785
resource representing a document's title	Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies
has PubMed Central identifier	PMC4086938
has PubMed identifier	25004134
schema:publication	PLoS One
resource representing a document's body	covid:0542a6ae26f57a5ffa35dcfebdec5004ff45688c#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/0542a6ae26f57a5ffa35dcfebdec5004ff45688c
is schema:about of	named entity 'VIRUS INFECTION' named entity 'influenza A' named entity 'outpatients' named entity 'Outcomes' named entity 'ORDER' named entity 'DATA' named entity 'INFLUENZA A' named entity 'OUTCOMES' named entity 'INTERNATIONAL' named entity 'COHORT STUDIES' named entity 'PLANNED' named entity 'INFLUENZA A' named entity 'RISK OF' named entity 'RESULTS' named entity 'OUTPATIENTS' named entity 'COHORT STUDIES' named entity 'EVALUATE' named entity 'OUTCOMES' named entity 'VIRUS' named entity 'LIMITED' named entity 'PROGRESSION' named entity 'ILLNESS' named entity 'ASSESS' named entity 'CLINICAL OUTCOMES' named entity 'PATIENTS' named entity 'MAJOR' named entity 'FLU' named entity 'HOSPITALIZED PATIENTS' named entity 'RISK FACTORS' named entity 'PROGNOSTIC FACTORS' named entity 'BACKGROUND' covid:arg/0542a6ae26f57a5ffa35dcfebdec5004ff45688c named entity 'progression' named entity 'limited' named entity 'factors' named entity 'Studies' named entity 'Results' named entity 'cohort studies' named entity 'FLU' named entity 'cohort studies' named entity 'Influenza' named entity '2009' named entity 'Logistic regression' named entity 'morbid obesity' named entity 'influenza-like illness' named entity 'virus infection' named entity 'child-bearing' named entity 'ILI' named entity 'follow-up' named entity 'BMI' named entity 'ICU' named entity 'risk factors' named entity 'World Health Organization' named entity 'Prognostic' named entity 'viruses' named entity 'epidemic' named entity 'ICU' named entity '95% CI' named entity 'neuraminidase inhibitors' named entity 'virus infection' named entity 'ILI' named entity 'Europe' named entity 'BMI' named entity 'Westmead Hospital' named entity 'follow-up'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software